- ►cardiobarbanza.com [PDF] DM Nathan, JB Buse, MB Davidson, E … - Diabetologia, 2009 - Springer Page 1. CONSENSUS STATEMENT UPDATE Medical management of hyperglycaemia in type
2 diabetes mellitus: a consensus algorithm for the initiation ... Cited by 1039 - Related articles - BL Direct - All 92 versions
I Raz, Y Chen, M Wu, S Hussain, KD Kaufman … - Current Medical Research and Opinion®, 2008 - informahealthcare.com Objective: The purpose of this study was to evaluate the efficacy and safety of
sitagliptin as an add-on to metformin therapy in patients with moderately severe
(hemoglobin A1c ≥8.0% and ≤11.0%) type 2 diabetes mellitus (T2DM). ... Cited by 33 - Related articles - BL Direct - All 4 versions
R Scott, T Loeys, MJ Davies, SS Engel… - Diabetes, obesity & metabolism, 2008 - ncbi.nlm.nih.gov Efficacy and safety of sitagliptin when added to ongoing metformin therapy in
patients with type 2 diabetes. ... Scott R, Loeys T, Davies MJ, Engel SS;
Sitagliptin Study 801 Group. ... Collaborators: Darnell D, Davis T, ... Cited by 30 - Related articles - All 2 versions
S Madsbad, T Krarup, CF Deacon, JJ Holst - Current Opinion in Clinical Nutrition & Metabolic Care, 2008 - journals.lww.com Recent findings: The injectable glucagon-like peptide-1 receptor agonists
exenatide significantly improves glycaemic control, with average reductions in
haemoglobin A1c of about 1.0%, fasting plasma glucose of about 1.4 mmol/l, ... Cited by 23 - Related articles - All 2 versions
- ►endojournals.org CW Chia, JM Egan - Journal of Clinical Endocrinology & Metabolism, 2008 - Endocrine Soc Evidence Synthesis: Exenatide and liraglutide are injection based. Three-year
follow-up data on exenatide showed a sustained weight loss and glycosylated
hemoglobin (HbA 1c ) reduction of 1%. Nausea and vomiting are common. ... Cited by 20 - Related articles - All 5 versions
A Karasik, P Aschner, H Katzeff, MJ Davies, … - Current Medical Research and Opinion®, 2008 - informahealthcare.com Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral
antihyperglycemic agents that enhance the body's ability to regulate blood
glucose by increasing the active levels of incretins, glucagon-like peptide ... Cited by 20 - Related articles - BL Direct - All 4 versions
- ►middlebury.edu [PDF] JJ Holst, T Vilsbøll, CF Deacon - Molecular and Cellular Endocrinology, 2009 - Elsevier The incretin hormones are released during meals from gut endocrine cells. They
potentiate glucose-induced insulin secretion and may be responsible for up to
70% of postprandial insulin secretion. The incretin hormones include ... Cited by 20 - Related articles - All 3 versions
- ►dvdres.com [PDF] JHB Scarpello, H Howlett - Diabetes & Vascular Disease Research, 2008 - dvr.sagepub.com Abstract M etformin is now established as a first-line antidiabetic therapy for
the management of type 2 diabetes. Its early use in treatment algo- rithms is
supported by lack of weight gain, low risk of hypoglycaemia and its mode of ... Cited by 15 - Related articles - All 8 versions
- ►cell.com EJP de Koning, S Bonner-Weir, TJ Rabelink - Trends in Pharmacological Sciences, 2008 - Elsevier Type 2 diabetes is characterized by progressive β-cell dysfunction and a
reduction in β-cell mass. Pancreatic islets are a target for adverse effectors
such as high concentrations of glucose, pro-inflammatory cytokines and ... Cited by 11 - Related articles - All 4 versions
JJ Holst, CF Deacon, T Vilsbøll, T Krarup, S … - Trends in Molecular Medicine, 2008 - Elsevier Incretins, enhancers of insulin secretion, are essential for glucose tolerance,
and a reduction in their function might contribute to poor β-cell function in
patients with type-2 diabetes mellitus. However, at supraphysiological ... Cited by 10 - Related articles - All 4 versions
